[go: nahoru, domu]

Jump to content

PPP1R14A

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
PPP1R14A
Identifiers
AliasesPPP1R14A, CPI-17, CPI17, PPP1INL, protein phosphatase 1 regulatory inhibitor subunit 14A
External IDsOMIM: 608153; MGI: 1931139; HomoloGene: 12267; GeneCards: PPP1R14A; OMA:PPP1R14A - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_033256
NM_001243947

NM_026731

RefSeq (protein)

NP_001230876
NP_150281

NP_081007

Location (UCSC)n/aChr 7: 28.99 – 28.99 Mb
PubMed search[2][3]
Wikidata
View/Edit HumanView/Edit Mouse

Protein phosphatase 1 regulatory subunit 14A also known as CPI-17 (C-kinase potentiated Protein phosphatase-1 Inhibitor Mr = 17 kDa) is a protein that in humans is encoded by the PPP1R14A gene.[4][5][6]

Function

CPI-17 is a phosphorylation-dependent inhibitor protein of smooth muscle myosin phosphatase, discovered in pig aortic homogenates. Phosphorylation of the Thr-38 residue converts the protein into a potent inhibitor for myosin phosphatase. A single phosphorylation of CPI-17 at Thr-38 triggers a global conformational change that causes re-alignment of four helices. Multiple kinases are identified to phosphorylate CPI-17, such as PKC, ROCK, PKN, ZIPK, ILK, and PAK. Agonist stimulation of smooth muscle enhances CPI-17 phosphorylation mainly through PKC and ROCK. Myosin phosphatase inhibition increases myosin phosphorylation and smooth muscle contraction in the absence of increased intracellular Ca2+ concentration. This phenomenon is known as Ca2+ sensitization, which occurs in response to agonist stimulation of smooth muscle. In Purkinje neuron, CPI-17 is involved in long-term synaptic depression.

There are three homologues of CPI-17:

  • Phosphatase Holoenzyme Inhibitor (PHI: PPP1R14B),
  • Kinase Enhanced Phosphatase Inhibitor (KEPI: PPP1R14C), and
  • Gastric-Brain Phosphatase Inhibitor (GBPI: PPP1R14D).

Clinical significance

CPI-17 is up-regulated some cancer cells, and causes hyperphosphorylation of tumor suppressor merlin/NF2.[7][6] In prostate cancer, CPI-17 expressions are reported to be associated with GWAS risk SNP rs7247241 T allele and increase cell proliferation. [8]

References

  1. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000037166Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ Eto M, Ohmori T, Suzuki M, Furuya K, Morita F (December 1995). "A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization". Journal of Biochemistry. 118 (6): 1104–1107. doi:10.1093/oxfordjournals.jbchem.a124993. PMID 8720121.
  5. ^ Yamawaki K, Ito M, Machida H, Moriki N, Okamoto R, Isaka N, et al. (July 2001). "Identification of human CPI-17, an inhibitory phosphoprotein for myosin phosphatase". Biochemical and Biophysical Research Communications. 285 (4): 1040–1045. doi:10.1006/bbrc.2001.5290. PMID 11467857.
  6. ^ a b "Entrez Gene: PPP1R14A protein phosphatase 1, regulatory (inhibitor) subunit 14A".
  7. ^ Eto M (December 2009). "Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of the CPI-17 family, C-kinase-activated PP1 inhibitors". The Journal of Biological Chemistry. 284 (51): 35273–35277. doi:10.1074/jbc.R109.059972. PMC 2790955. PMID 19846560.
  8. ^ Tian Y, Soupir A, Liu Q, Wu L, Huang CC, Park JY, Wang L (November 2021). "Novel role of prostate cancer risk variant rs7247241 on PPP1R14A isoform transition through allelic TF binding and CpG methylation". Human Molecular Genetics. 31 (10): 1610–1621. doi:10.1093/hmg/ddab347. PMC 9122641. PMID 34849858.

Further reading